Asthma control in adult patients treated with a combination of inhaled corticosteroids and long-acting beta-2 agonists: a prospective observational study

Rogala, Barbara; Majak, Paweł; Glück, Joanna; Dębowski, Tomasz

doi:10.20452/pamw.3899

Cited by 12 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean change in AQLQ total score from baseline to the end of the study (0.85) and the mean changes in each domain (0.63e1.02) all exceeded the minimum change of 0.5, which is defined as the minimal clinically important difference for this instrument [30]. The increase in the number of patients with asthma control from 30.9% at baseline to 62.4% at the end of the study was comparable to that observed in a recent noninterventional study including 5789 asthma patients receiving three different ICS/LABA combinations over six months [31]. These data suggest that initiation of FP/FORM therapy was associated with clinically relevant improvements in disease status and in patients' quality of life.…”

Section: Discussionsupporting

confidence: 63%

Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

Schmidt

Petro

Hoheisel

et al. 2017

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 63%

Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

Schmidt

Petro

Hoheisel

et al. 2017

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Effects of obesity on asthma: immunometabolic links Sarah Miethe 1 , Maria Guarino 2,3,4 , Fahd Alhamdan 1 , Hans -Uwe Simon 5 , Harald Renz 1,6 , Jean -François Dufour 2,3 , Daniel P. Potaczek 1,6,7 *, Holger Garn 1 * test for the identification of atopic asthma at a young age is available. 3 Still, several of its characteristics have been rather uniformly described (FIGURE 1).…”

Section: Review Articlementioning

confidence: 99%

“…1,2 Asthma is a widespread chronic inflammatory disease, which has a highly heterogeneous pathogenesis and clinical picture. 3,4 Asthma has been defined by the National Heart, Lung, and Blood Institute as a "common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation". 5 General symptoms include coughing, wheezing, or shortness of breath.…”

Section: Introductionmentioning

confidence: 99%

The effects of obesity on asthma: immunometabolic links

Miethe¹,

Guarino²,

Alhamdan³

et al. 2018

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Asthma is a widespread chronic inflammatory disease, which has a highly heterogeneous etiopathogenesis, with predominance of either T‑helper cell type 2 (Th2; type 2) or non-Th2 (non-type 2) mechanisms. Together with cardiovascular or autoimmune diseases, obesity, and others, asthma belongs to so called noncommunicable diseases, a group of disorders with immunometabolic links as underlying mechanisms. So far, obesity and asthma have been considered mostly independently, but there are clear signs of relevant interactions. First, obese patients are at increased risk of asthma or asthma‑like symptoms. Second, asthma accompanied by obesity is more severe and more difficult to treat. A specific phenotype called obesity‑associated asthma has been also described, which is late‑onset, rather severe, non-type 2‑driven disease, present mostly in women. In addition, obesity can coincide with asthma also in children, and, although obesity generally skews the Th1/Th2 balance towards Th1, it can also accompany type 2‑driven asthma. However, those combinations represent less precisely defined disease entities. Despite a substantial increase in our knowledge on the mechanisms mediating the effects of obesity on the development of asthma in several recent years, still much needs to be done, especially on the molecular level.

show abstract

“…It is important to note that 22.6% of interviewed doctors in the present study prescribed the use of combined inhaled glucocorticoids and LABA, which is highly recommended by global opinion-forming organisations and confirmed by several studies [4,5,14,15]. However, the majority of asthma cases are mild, allowing the basic application of ICS alone, with the option of dose manipulation [4].…”

Section: Discussionmentioning

confidence: 60%

“…Although our study did not include the severity of asthma, the data concerning www.journals.viamedica.pl the percentage of the mild asthma cases revealed doubts behind the prevalent use of the combined method [4]. Assuming that recommendations existed for the chronic use of combined inhaled glucocorticoids and LABA administration, the medications would have to be administrated together in most cases, via a single inhaler [4,5,15,16]. However, it was identified that in Poland these medications are applied separately.…”

Section: Discussionmentioning

confidence: 99%

Selected Aspects of Medical Care for Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Poland

Miłkowska-Dymanowska¹,

Białas²,

Górski³

2017

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Noncompliance with healthcare undoubtedly has a strong influence on the high prevalence of uncontrolled obstructive diseases. The aim of our study was to evaluate the quality of medical conduct in patients with asthma or chronic obstructive lung diseases (COPD), with encompassed two-levelled system of health care. Material and methods: A survey of general practitioners (GP), allergists and pulmonologists practicing in Poland was performed between September and December 2016. The basic survey included the data concerning the number of treated patients, the course of the visits, treatment regimens and whether the patients follow the instructions of the physician. The specialist survey recorded the details of the specialist visits, their frequency and character, an evaluation of the pharmacological and non-pharmacological therapies and an evaluation of the GP's actions. Results: The basic questionnaire was completed by 807 doctors with an average of 21 ± 9.85 years of medical experience. Most of the interviewed individuals were GPs (56%), followed by pulmonologists (28%) and allergists (16%). The GP reported 47 cases/month with obstructive pulmonary conditions, including 48.94% asthma and 51.06% COPD patients. They diagnosed three new asthma and COPD patients per month. The allergists treated patients with asthma (105 patients/ /month), with 19 newly-diagnosed patients/month. The pulmonologists treated fewer asthma cases than COPD: 71 and 98 patients respectively. They reported 14 patients/month of newly-diagnosed COPD cases. The patients took inhaled glucocorticoids and long-acting b adrenoceptor agonists in separate inhalers. The most frequently-used device was a disc. In opinion of the specialists, half of the therapies initiated recently by GPs for patients with asthma and COPD required modifications. Conclusions: There is a disparity between the true state of medical care of asthma and COPD patients and globally-accepted standards.

show abstract

Asthma control in adult patients treated with a combination of inhaled corticosteroids and long-acting beta-2 agonists: a prospective observational study

Cited by 12 publications

References 23 publications

Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

The effects of obesity on asthma: immunometabolic links

Selected Aspects of Medical Care for Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Poland

Contact Info

Product

Resources

About